Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
A highly prevalent condition among adults worldwide, MASLD is associated with liver-related complications, hepatocellular carcinoma, cardiovascular disease, and certain extrahepatic cancers. First-line treatment includes behavioral modifications, including a weight-reducing diet, physical exercise, and avoidance of alcohol. Resmetirom and semaglutide are conditionally FDA-approved medications for the treatment of adults with MASH and moderate to advanced fibrosis.
Authors
- Norbert Stefan (ORCID: https://orcid.org/0000-0002-2186-9595)
- Herbert Tilg
- Veronica Salvatore (ORCID: https://orcid.org/0000-0001-9238-5080)
- Giovanni Targher
Institutions
- University of Verona (IT)
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Ospedale Sacro Cuore Don Calabria (IT)
- Department of Health (ES)
- German Center for Diabetes Research (DE)
- University of Tübingen (DE)
Publication Details
- Journal
- JAMA
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1001/jama.2025.19615
- Citations
- 30
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 40.63